secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001628280-24-045000
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn posts Q3 net loss of $19.1M; first patient dosed in Phase 1 for FHD-909
-------------------------------------------------------------------------------

- Revenue $7.8M vs $17.5M year ago; net loss $19.1M vs $14.3M year ago.
- Cash $267.4M as of Sept 30, 2024; expects cash runway into 2027.
- First patient dosed with FHD-909 (SMARCA2 inhibitor) in Phase 1 for SMARCA4 mutant NSCLC.
- Topline Phase 1 data for FHD-286 + decitabine in AML expected by year-end 2024.
- Appointed Anna Rivkin as Chief Business Officer in September 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024045000/0001628280-24-045000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024045000/fhtx-20241104.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer